Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders

Overview

Journal ACS Cent Sci

Specialty Chemistry

Date 2022 May 4

PMID 35505873

Authors

Pallavi M Gosavi

Kevin C Ngan

Megan J R Yeo

Cindy Su

Jiaming Li

Nicholas Z Lue

Samuel M Hoenig

Brian B Liau

Affiliations

Soon will be listed here.

Abstract

Targeted protein degradation (TPD) holds immense promise for drug discovery, but mechanisms of acquired resistance to degraders remain to be fully identified. Here, we used clustered regularly interspaced short palindromic repeats (CRISPR)-suppressor scanning to identify mechanistic classes of drug resistance mutations to molecular glue degraders in GSPT1 and RBM39, neosubstrates targeted by E3 ligase substrate receptors cereblon and DCAF15, respectively. While many mutations directly alter the ternary complex heterodimerization surface, distal resistance sites were also identified. Several distal mutations in RBM39 led to modest decreases in degradation, yet can enable cell survival, underscoring how small differences in degradation can lead to resistance. Integrative analysis of resistance sites across GSPT1 and RBM39 revealed varying levels of sequence conservation and mutational constraint that control the emergence of different resistance mechanisms, highlighting that many regions co-opted by TPD are nonessential. Altogether, our study identifies common resistance mechanisms for molecular glue degraders and outlines a general approach to survey neosubstrate requirements necessary for effective degradation.

Citing Articles

UM171 glues asymmetric CRL3-HDAC1/2 assembly to degrade CoREST corepressors.

Yeo M, Zhang O, Xie X, Nam E, Payne N, Gosavi P Nature. 2025; 639(8053):232-240.

PMID: 39939761 PMC: 11882444. DOI: 10.1038/s41586-024-08532-4.

Implications of frequent hitter E3 ligases in targeted protein degradation screens.

Zhang X, Simon G, Cravatt B Nat Chem Biol. 2025; .

PMID: 39870762 DOI: 10.1038/s41589-024-01821-z.

Targeted protein degradation: from mechanisms to clinic.

Tsai J, Nowak R, Ebert B, Fischer E Nat Rev Mol Cell Biol. 2024; 25(9):740-757.

PMID: 38684868 DOI: 10.1038/s41580-024-00729-9.

Multiplexed, multimodal profiling of the intracellular activity, interactions, and druggability of protein variants using LABEL-seq.

Simon J, Fowler D, Maly D bioRxiv. 2024; .

PMID: 38659825 PMC: 11042325. DOI: 10.1101/2024.04.19.590094.

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.

Hong S, Divakaran A, Osa A, Huang O, Wertz I, Nomura D ACS Chem Biol. 2024; 19(2):442-450.

PMID: 38305738 PMC: 10999000. DOI: 10.1021/acschembio.3c00642.

References

Donovan K, Ferguson F, Bushman J, Eleuteri N, Bhunia D, Ryu S . Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020; 183(6):1714-1731.e10. PMC: 10294644. DOI: 10.1016/j.cell.2020.10.038. View

Wang E, Lu S, Pastore A, Chen X, Imig J, Chun-Wei Lee S . Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell. 2019; 35(3):369-384.e7. PMC: 6424627. DOI: 10.1016/j.ccell.2019.01.010. View

Jiang B, Gao Y, Che J, Lu W, Kaltheuner I, Dries R . Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol. 2021; 17(6):675-683. PMC: 8590456. DOI: 10.1038/s41589-021-00765-y. View

Wu T, Yoon H, Xiong Y, Dixon-Clarke S, Nowak R, Fischer E . Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. Nat Struct Mol Biol. 2020; 27(7):605-614. PMC: 7923177. DOI: 10.1038/s41594-020-0438-0. View

Uehara T, Minoshima Y, Sagane K, Sugi N, Mitsuhashi K, Yamamoto N . Selective degradation of splicing factor CAPERα by anticancer sulfonamides. Nat Chem Biol. 2017; 13(6):675-680. DOI: 10.1038/nchembio.2363. View

Schoonenberg V, Cole M, Yao Q, Macias-Trevino C, Sher F, Schupp P . CRISPRO: identification of functional protein coding sequences based on genome editing dense mutagenesis. Genome Biol. 2018; 19(1):169. PMC: 6195731. DOI: 10.1186/s13059-018-1563-5. View

Kronke J, Fink E, Hollenbach P, MacBeth K, Hurst S, Udeshi N . Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015; 523(7559):183-188. PMC: 4853910. DOI: 10.1038/nature14610. View

Barrio S, Munawar U, Zhu Y, Giesen N, Shi C, Da Via M . IKZF1/3 and CRL4 E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2019; 105(5):e237-e241. PMC: 7193510. DOI: 10.3324/haematol.2019.217943. View

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y . Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-50. DOI: 10.1126/science.1177319. View

10.

Mayor-Ruiz C, Jaeger M, Bauer S, Brand M, Sin C, Hanzl A . Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. Mol Cell. 2019; 75(4):849-858.e8. DOI: 10.1016/j.molcel.2019.07.013. View

11.

Sievers Q, Petzold G, Bunker R, Renneville A, Slabicki M, Liddicoat B . Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018; 362(6414). PMC: 6326779. DOI: 10.1126/science.aat0572. View

12.

Nguyen T, Li J, Lu C, Mamrosh J, Lu G, Cathers B . p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc Natl Acad Sci U S A. 2017; 114(14):3565-3571. PMC: 5389304. DOI: 10.1073/pnas.1700949114. View

13.

Sher F, Hossain M, Seruggia D, Schoonenberg V, Yao Q, Cifani P . Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nat Genet. 2019; 51(7):1149-1159. PMC: 6650275. DOI: 10.1038/s41588-019-0453-4. View

14.

Kortum K, Mai E, Hanafiah N, Shi C, Zhu Y, Bruins L . Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016; 128(9):1226-33. PMC: 5524534. DOI: 10.1182/blood-2016-02-698092. View

15.

Ting T, Goralski M, Klein K, Wang B, Kim J, Xie Y . Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15. Cell Rep. 2019; 29(6):1499-1510.e6. PMC: 7950731. DOI: 10.1016/j.celrep.2019.09.079. View

16.

Ottis P, Palladino C, Thienger P, Britschgi A, Heichinger C, Berrera M . Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. ACS Chem Biol. 2019; 14(10):2215-2223. DOI: 10.1021/acschembio.9b00525. View

17.

Shirasaki R, Matthews G, Gandolfi S, De Matos Simoes R, Buckley D, Raja Vora J . Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021; 34(1):108532. PMC: 8485877. DOI: 10.1016/j.celrep.2020.108532. View

18.

Gooding S, Ansari-Pour N, Towfic F, Estevez M, Chamberlain P, Tsai K . Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021; 137(2):232-237. PMC: 7893409. DOI: 10.1182/blood.2020007081. View

19.

Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting T . Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science. 2017; 356(6336). DOI: 10.1126/science.aal3755. View

20.

Kronke J, Udeshi N, Narla A, Grauman P, Hurst S, McConkey M . Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2013; 343(6168):301-5. PMC: 4077049. DOI: 10.1126/science.1244851. View